Skip to content
Clinical Trials – home
Not yet recruiting

Efficacy and Safety of Remibrutinib (LOU064) in Adults and Adolescents with Food Allergy

Verified siteFast replyRegistered drug
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

A clinical investigation is being conducted in people who have Food allergy, a condition in which the immune system reacts strongly to certain foods such as peanuts, milk, or egg, causing symptoms that can range from mild itching to severe breathing problems. The study evaluates the effect of an oral medication called remibrutinib (LOU064), which is taken twice daily, compared with an inactive tablet (placebo).

The purpose of the study is to determine whether the medication helps participants tolerate larger amounts of the allergenic foods without serious reactions. Over the course of about one year, participants are randomly assigned to receive either the active drug or the placebo, and neither they nor the study staff know which they receive (double‑blind). At several visits, participants undergo medically supervised food challenge tests in which increasing doses of peanut protein, milk protein, or egg protein are given to see the highest amount they can safely eat.

Throughout the trial, participants are closely monitored for any side effects, changes in vital signs, and overall health. The amount of each food protein that can be tolerated and the severity of any symptoms are recorded to assess the medication’s safety and effectiveness.

The research process

The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and Start of Study Medication

    After joining the study, you are randomly assigned to receive either remibrutinib or a matching placebo. The assignment is unknown to you and the study staff (double‑blind).

    You receive a supply of film‑coated tablets that contain either 75 mg of remibrutinib or no active drug (placebo).

  2. Step 2

    Taking the Study Drug Twice Daily

    You take one tablet in the morning and one tablet in the evening, every day, for the first 24 weeks of the double‑blind period.

    Each tablet provides 75 mg of remibrutinib, so the total daily dose is 150 mg when you are on the active treatment.

    If you are assigned to the placebo, you follow the same schedule with tablets that contain no active ingredient.

  3. Step 3

    Regular Safety Monitoring

    During the double‑blind period you attend clinic visits at predetermined times (for example, every 4 weeks).

    At each visit the study staff measure your vital signs (blood pressure, pulse), perform an electrocardiogram (ECG) to check heart rhythm, and collect blood samples for laboratory tests.

    Any adverse events (new or worsening symptoms) are recorded and evaluated.

  4. Step 4

    First Double‑Blind Food Challenge (Week 4)

    At week 4 you undergo a double‑blind, placebo‑controlled food challenge (DBPCFC) with the allergen that matches your known food allergy (peanut, milk, or egg).

    The challenge uses a specially prepared meal that contains incremental amounts of the relevant protein. Each dose consists of 5 044 mg of granules, which corresponds to a specific amount of the food protein.

    The challenge starts with a very small dose and the amount is increased stepwise until you either reach the target dose (≥ 600 mg of peanut protein or ≥ 1 000 mg of milk or egg protein) or develop dose‑limiting symptoms (significant allergic reactions).

    Both the active drug and the placebo are continued during the challenge, and the staff do not know which you are receiving.

  5. Step 5

    Continued Treatment and Monitoring (Weeks 5‑23)

    You keep taking the study tablets twice daily and attend the scheduled safety visits.

    The study team continues to record any adverse events and checks laboratory values, vital signs, and ECG results.

  6. Step 6

    Second Double‑Blind Food Challenge (Week 24)

    At week 24 you repeat the DBPCFC with the same type of allergen (peanut, milk, or egg).

    The procedure is identical to the week 4 challenge, aiming to determine whether you can tolerate a larger amount of the protein (≥ 600 mg of peanut protein or ≥ 1 000 mg of milk or egg protein) without dose‑limiting symptoms.

    The results of this challenge are the primary measure of the study’s effectiveness.

  7. Step 7

    End of Double‑Blind Period and Transition to Open‑Label

    After the week 24 challenge the double‑blind phase ends. All participants, regardless of the original assignment, are offered the same open‑label treatment for the remaining 28 weeks.

    In the open‑label phase you continue to take one tablet in the morning and one in the evening, now knowing that the tablet contains remibrutinib.

  8. Step 8

    Open‑Label Treatment and Ongoing Assessments (Weeks 25‑52)

    You keep taking the 75 mg tablets twice daily for the rest of the 52‑week study.

    Clinic visits continue on the same schedule to monitor safety (vital signs, ECG, laboratory tests) and to record any new adverse events.

    No additional food challenges are performed after week 24, but the study team continues to evaluate your overall health and any changes in allergy symptoms.

  9. Step 9

    Final Study Visit and Study Completion

    At week 52 you attend a final study visit. The study staff perform a comprehensive safety assessment, including vital signs, ECG, and laboratory tests.

    All study medication is returned, and the study is formally concluded for you.

    The collected data will be used to determine the overall safety and efficacy of remibrutinib for people with food allergy.

Who can join the trial?

6 criteria

  • Provide a signed informed consent form (and, if you are a teenager, also a signed assent form) before any study procedures begin.
  • Be between 12 and 65 years old at the time you sign the consent form.
  • Show a positive result on a blood test that measures allergen‑specific IgE (a type of antibody) of at least 0.35 kUA/L for peanut, milk, or egg.
  • Have a positive Skin Prick Test (SPT) for peanut, milk, or egg, meaning the raised bump (called a wheal) on your skin is 4 mm or larger compared with the control.
  • Experience a positive result on a baseline double‑blind placebo‑controlled food challenge (DBPCFC), which means you develop dose‑limiting symptoms when you receive a single dose of either ≤ 100 mg of peanut protein or ≤ 300 mg of milk or egg protein.
  • Be able to take part in the DBPCFC procedure and be willing to avoid eating peanut, milk (both cooked and uncooked), egg (both cooked and uncooked), and any other foods you are allergic to for the whole study.

Who cannot join the trial?

5 criteria

  • You have previously taken remibrutinib or other medicines that block a protein called BTK (Bruton’s tyrosine kinase).
  • You have a known allergy or strong reaction (hypersensitivity) to the study drug, any of its inactive ingredients (excipients), or to medicines that are chemically similar.
  • You are allergic or cannot tolerate any of the ingredients used in the test mixture (matrix components) for the food challenge.
  • You experienced serious symptoms (dose‑limiting symptoms) when you received the placebo food during the initial test (baseline DBPCFC, which stands for double‑blind, placebo‑controlled food challenge).
  • The doctor believes that, based on your medical exam, health conditions, or lab test results, you are not suitable for the study.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Remibrutinib (LOU064)

    an oral tablet that blocks a protein called BTK, which helps reduce allergic reactions. In this study participants take it to see if it lets them eat more of the food they are allergic to without having a reaction.

  • Milk challenge meal

    a powdered skimmed milk that is mixed into a drink for the test. It is given to participants to check how much milk protein they can tolerate while on the study medication.

  • Egg challenge meal

    a powdered form of ovalbumin (the main protein in egg whites). It is mixed into a drink and given to participants to see how much egg protein they can safely eat during the trial.

  • Peanut challenge meal (PCM001)

    a powdered defatted peanut extract. It is mixed into a drink and used to test the amount of peanut protein participants can handle while taking the study drug.

  • Salbutamol

    a fast‑acting inhaled medicine that relaxes the muscles in the airways. It is kept on hand in case a participant develops breathing problems during the food challenge.

  • Epinephrine

    a medication given by injection that quickly treats severe allergic reactions (anaphylaxis). It is available as emergency treatment if a serious reaction occurs during the study.

What is already known about the treatment

  • Remibrutinib (LOU064)

    This drug is taken as an oral film‑coated tablet that is swallowed whole. It is currently an investigational medicine being studied in clinical trials for allergic conditions such as food allergy. The main use being explored is to reduce allergic reactions by blocking a protein called Bruton’s tyrosine kinase, which helps stop immune cells from over‑reacting. It belongs to the class of Bruton’s tyrosine kinase (BTK) inhibitors, a type of targeted therapy.

  • Salbutamol

    Salbutamol is usually inhaled through a small inhaler device, delivering the medicine directly to the lungs. It is an approved, widely used drug for relieving asthma symptoms and other breathing problems caused by narrowed airways. It works by activating beta‑2 receptors in the airway muscles, causing them to relax and open up. Salbutamol is classified as a short‑acting beta‑2 agonist.

  • Epinephrine

    Epinephrine is given by injection, often with an auto‑injector that is pressed against the thigh. It is an approved emergency treatment for severe allergic reactions (anaphylaxis) and for cardiac arrest. The drug quickly narrows blood vessels and opens the airways by stimulating both alpha and beta receptors, helping the body recover from a life‑threatening reaction. Epinephrine is classified as a non‑selective adrenergic agonist.

Investigated diseases

  • Peanut allergy

    The immune system reacts to proteins in peanuts, causing symptoms after ingestion. Reactions can start with mild itching and progress to more widespread symptoms if larger amounts are consumed. The condition is chronic; individuals remain sensitive over time. Exposure to even trace amounts can trigger symptoms. Symptoms may increase in severity with repeated exposures. The allergy typically begins in childhood but can persist.

  • Cow's milk allergy

    This is an immune response to proteins in cow's milk that leads to symptoms after drinking or eating milk products. Early reactions may include skin redness or stomach upset, and with higher intake, symptoms can spread to other parts of the body. The sensitivity is usually present from infancy and may change over time. Small amounts can still cause a reaction. The condition can evolve, with some children outgrowing it while others continue to be affected.

  • Egg allergy

    The immune system reacts to proteins in egg whites or yolks, causing symptoms when eggs are consumed. Initial signs may be mild skin irritation, and larger exposures can lead to more extensive reactions. The allergy is often identified in early childhood and can persist. Even tiny quantities of egg protein may provoke a response. The pattern of reactions can vary with the amount and form of egg ingested.

Trial detailsLast updated 22 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2024-519159-28-00Protocol codeCLOU064I12301Estimated enrolment420 patientsSponsorNovartis Pharma AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.